PharmChem, Inc. Announces Acquisition by Alcohol Monitoring Systems, Inc.
PharmChem (OTC: PCHM), a leading provider of sweat patches for drug abuse detection, has announced its acquisition by Alcohol Monitoring Systems, Inc. for $3.75 per share in cash. The deal represents a 22% premium over PharmChem's closing price of $3.07 on January 31, 2025.
The transaction, unanimously approved by PharmChem's board of directors, has already secured support agreements for 52% of outstanding shares. The acquisition is expected to close by the end of Q3 2025, subject to shareholder approval and customary closing conditions. This strategic move aims to expand Alcohol Monitoring Systems' capabilities into drug testing while complementing their existing alcohol and location monitoring technologies portfolio.
PharmChem (OTC: PCHM), un fornitore leader di cerotti per il rilevamento dell'abuso di sostanze, ha annunciato la sua acquisizione da parte di Alcohol Monitoring Systems, Inc. per 3,75 $ per azione in contanti. L'accordo rappresenta un premio del 22% rispetto al prezzo di chiusura di PharmChem di 3,07 $ il 31 gennaio 2025.
La transazione, approvata all'unanimità dal consiglio di amministrazione di PharmChem, ha già ottenuto accordi di supporto per il 52% delle azioni in circolazione. L'acquisizione dovrebbe concludersi entro la fine del terzo trimestre 2025, subordinatamente all'approvazione degli azionisti e alle consuete condizioni di chiusura. Questa mossa strategica mira ad ampliare le capacità di Alcohol Monitoring Systems nel campo dei test antidroga, integrando il loro portafoglio esistente di tecnologie per il monitoraggio dell'alcol e della posizione.
PharmChem (OTC: PCHM), un proveedor líder de parches para la detección de abuso de drogas, ha anunciado su adquisición por parte de Alcohol Monitoring Systems, Inc. por 3,75 $ por acción en efectivo. El acuerdo representa una prima del 22% sobre el precio de cierre de PharmChem de 3,07 $ el 31 de enero de 2025.
La transacción, aprobada por unanimidad por la junta directiva de PharmChem, ya cuenta con acuerdos de apoyo para el 52% de las acciones en circulación. Se espera que la adquisición se cierre antes de finales del tercer trimestre de 2025, sujeta a la aprobación de los accionistas y las condiciones habituales de cierre. Esta estrategia busca ampliar las capacidades de Alcohol Monitoring Systems en pruebas de drogas, complementando su portafolio existente de tecnologías para el monitoreo de alcohol y ubicación.
PharmChem (OTC: PCHM)� 약물 남용 감지� 위한 땀 패치� 선도적인 공급업체�, Alcohol Monitoring Systems, Inc.� 의해 주당 3.75달러 현금� 인수되었다고 발표했습니다. � 거래� 2025� 1� 31� PharmChem 종가 3.07달러 대� 22% 프리미엄� 의미합니�.
PharmChem 이사회의 만장일치 승인으로 진행� 이번 거래� 이미 발행 주식� 52%� 대� 지지 계약� 확보했습니다. 인수� 주주 승인 � 일반적인 마감 조건� 충족하는 것을 전제� 2025� 3분기 말까지 완료� 예정입니�. � 전략� 조치� Alcohol Monitoring Systems가 기존� 알코� � 위치 모니터링 기술 포트폴리오를 보완하면� 약물 검� 역량� 확장하는 � 목적� 있습니다.
PharmChem (OTC : PCHM), un fournisseur leader de patchs transdermiques pour la détection de la consommation de drogues, a annoncé son acquisition par Alcohol Monitoring Systems, Inc. pour 3,75 $ par action en espèces. Cette opération représente une prime de 22 % par rapport au cours de clôture de PharmChem à 3,07 $ le 31 janvier 2025.
La transaction, approuvée à l'unanimité par le conseil d'administration de PharmChem, a déjà obtenu des accords de soutien pour 52 % des actions en circulation. L'acquisition devrait être finalisée d'ici la fin du troisième trimestre 2025, sous réserve de l'approbation des actionnaires et des conditions habituelles de clôture. Cette démarche stratégique vise à étendre les capacités d'Alcohol Monitoring Systems dans le domaine des tests de dépistage de drogues, tout en complétant leur portefeuille existant de technologies de surveillance de l'alcool et de la localisation.
PharmChem (OTC: PCHM), ein führender Anbieter von Schweißpflastern zur Erkennung von Drogenmissbrauch, hat seine Übernahme durch Alcohol Monitoring Systems, Inc. ü 3,75 $ pro Aktie in bar bekannt gegeben. Das Angebot stellt eine 22%ige Prämie gegenüber dem Schlusskurs von PharmChem von 3,07 $ am 31. Januar 2025 dar.
Die Transaktion, die einstimmig vom PharmChem-Vorstand genehmigt wurde, hat bereits Unterstützungsvereinbarungen ü 52% der ausstehenden Aktien gesichert. Die Übernahme soll bis Ende des dritten Quartals 2025 abgeschlossen sein, vorbehaltlich der Zustimmung der Aktionäre und der üblichen Abschlussbedingungen. Dieser strategische Schritt zielt darauf ab, die Fähigkeiten von Alcohol Monitoring Systems im Bereich Drogentests zu erweitern und gleichzeitig ihr bestehendes Portfolio an Alkohol- und Standortüberwachungstechnologien zu ergänzen.
- Acquisition price represents a 22% premium over recent share price
- Strong shareholder support with 52% of shares already committed
- Strategic fit with buyer's existing technology portfolio
- Potential for expanded product reach and market opportunities
- Enhanced resources and growth opportunities for employees
- Loss of independence as standalone company
- Shareholders will no longer participate in potential future upside beyond $3.75 per share
The
Interim CEO, Thompson Clark noted, "We conducted a robust process, had a number of interested parties and indications of interest, and are pleased that we were able to have PharmChem join with a company where the product's reach can be expanded, our customers better served, and our employees have more opportunity to grow. It is not every day that a deal is achieved that is a win for all stakeholders, but this is one of those days."
Alcohol Monitoring Systems, Inc.'s CEO, Chris Linthwaite said, "Our core mission is improving human lives and overall public safety through compliance based products and services. This acquisition expands our organizational capabilities into drug testing and complements our industry leading portfolio of alcohol and location monitoring technologies. Our customers are tackling tremendous complexity in accomplishing their public safety mission and SCRAM Systems is committed to expanding our capabilities to meet these growing needs."
The transaction is subject to approval of PharmChem's shareholders and other customary closing conditions and is expected to close before the end of the third quarter. The proposed transaction was unanimously approved by the PharmChem board of directors. The Company is in receipt of support agreements related to
If shareholders have questions, please email our CFO Shana Veale at [email protected].
վ
Chairman of the Board
About PharmChem, Inc.
PharmChem, Inc. ("PharmChem") (OTC: PCHM), headquartered in
Safe Harbor for Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The statements contained in this communication that are not purely historical are forward-looking statements. These forward-looking statements contain words such as, but not limited to, "expect," "anticipate," "estimate," "believe," "will," "may" or "might" and variations of such words and similar expressions. Such statements are subject to risks and uncertainties that are often difficult to predict and beyond the Company's control and could cause the Company's results to differ materially from those described. These risks and uncertainties and other factors include, but are not limited to, risks associated with this transaction, including the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement; the inability to complete the transaction due to the failure to satisfy the conditions to completion of the transaction; the risk of litigation related to the proposed transaction; the diversion of management time from ongoing business operations and opportunities as a result of the proposed transaction; the risk of adverse reactions or changes to business or employee relationships, including those resulting from the announcement or completion of the proposed transaction; adverse economic conditions; unanticipated changes to key personnel; changes in legislation or governmental regulations; changes in customer preferences for our products; changes in strategic relationships; supply chain constraints and disruptions; and force majeure events. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
View original content to download multimedia:
SOURCE PharmChem, Inc.